Search results
The section defines “non-opioid treatment” in part as “an implantable, reusable, or disposable medical device cleared or approved by the FDA for the intended use of managing or treating pain.”
COMPREHENSIVE ADDICTION AND RECOVERY ACT (CARA) 3.0. The COVID-19 crisis has exacerbated America’s deadly drug epidemic. Due to despair, unemployment, and substance abuse, addiction is rising in America.
The Comprehensive Addiction and Recovery Act (CARA) establishes a comprehensive, coordinated, balanced strategy through enhanced grant programs that would expand prevention and education efforts while also promoting treatment and recovery.
23 maj 2016 · Summary. The Comprehensive Addiction and Recovery Act of 2016 (CARA; S. 524) aims to address the problem of opioid addiction in the United States. It passed the Senate (S. 524 ES) on March 10, 2016, and it passed the House with an amendment in the nature of a substitute (S. 524 EAH) on May 13, 2016.
26 maj 2022 · This summary highlights keys findings from the Comprehensive Addiction and Recovery Act (CARA) Local Drug Crises Program National Cross-Site Evaluation (additional details found in the full...
(PDF - 3 pages, 51 KB) Identifies essential actions that Federal agencies must take immediately to effectively assist recipients in meeting reporting requirements associated with Section 1512 of the Recovery Act and to register and upload required information to FederalReporting.gov before the October 10, 2009, deadline.
14 paź 2011 · All ARRA-funded, NIH extramural grant or cooperative agreement recipients must report information in accordance with Section 1512 of the Recovery Act on a quarterly basis using the www.FederalReporting.gov Web site.
